In the last trading session, 1.56 million shares of the Lexeo Therapeutics Inc (NASDAQ:LXEO) were traded, and its beta was 3.80. Most recently the company’s share price was $2.50, and it changed around $0.16 or 6.84% from the last close, which brings the market valuation of the company to $82.66M. LXEO currently trades at a discount to its 52-week high of $19.50, offering almost -680.0% off that amount. The share price’s 52-week low was $2.32, which indicates that the current value has risen by an impressive 7.2% since then.
Lexeo Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.14. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended LXEO as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Lexeo Therapeutics Inc is expected to report earnings per share of -0.78 for the current quarter.
Lexeo Therapeutics Inc (NASDAQ:LXEO) trade information
Instantly LXEO has showed a green trend with a performance of 6.84% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.44 on recent trading dayincreased the stock’s daily price by 27.33%. The company’s shares are currently down -62.01% year-to-date, but still down -25.93% over the last five days. On the other hand, Lexeo Therapeutics Inc (NASDAQ:LXEO) is -53.96% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $28, which translates to bulls needing to increase their stock price by 91.07% from its current value. Analyst projections state that LXEO is forecast to be at a low of $28 and a high of $28.
Forecasts for the next quarter put sales growth at 0.00%.
Lexeo Therapeutics Inc earnings are expected to increase by 74.84% in 2025, but the outlook is positive 36.87% per year for the next five years.
LXEO Dividends
Lexeo Therapeutics Inc’s next quarterly earnings report is expected to be released in April.
Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Janus Henderson Global Life Sciences Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 1.53 shares worth $3.81 million, making up 4.61% of all outstanding shares. On the other hand, Janus Henderson Global Life Sciences Fund held roughly 731.18 shares worth around $1.83 million, which represents about 2.21% of the total shares outstanding.
